Frequent alteration of p16INK4a/p14ARF and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14ARF expression both correlate with poor prognosis

Journal of Pathology

Volumn 207, Issue 4, 2005, Pages 410-421

  Oda, Yoshinao ^a   Yamamoto, Hidetaka ^a   Takahira, Tomonari ^a   Kobayashi, Chikashi ^a   Kawaguchi, Kenichi ^a   Tateishi, Naomi ^a   Nozuka, Yoko ^a   Tamiya, Sadafumi ^a   Tanaka, Kazuhiro ^a   Matsuda, Shuichi ^a   Yokoyama, Ryohei ^b   Iwamoto, Yukihide ^a   Tsuneyoshi, Masazumi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

Myxoid round cell liposarcoma; p14ARF; p16INK4a; p53; Prognosis

Indexed keywords

KI 67 ANTIGEN; PROTEIN MDM2; PROTEIN P14ARF; PROTEIN P16INK4A; PROTEIN P53;

ADULT; ARTICLE; CANCER GRADING; CANCER LOCALIZATION; CANCER RISK; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CORRELATION ANALYSIS; FEMALE; FROZEN SECTION; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC RISK; GENETIC SUSCEPTIBILITY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MULTIVARIATE ANALYSIS; MUTATIONAL ANALYSIS; MYXOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN METHYLATION; RISK ASSESSMENT; SURVIVAL RATE; TUMOR SUPPRESSOR GENE; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; AGED; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENES, P53; HUMANS; IMMUNOENZYME TECHNIQUES; LIPOSARCOMA, MYXOID; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; SOFT TISSUE NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 29744463936     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1848     Document Type: Article

References (40)

1. Antonescu C, Ladanyi M. Myxoid liposarcoma. In WHO Classification of Tumours: Pathology and Genetics: Tumours of Soft Tissue and Bone, Fletcher CDM, Unni KK, Mertens F (eds). IARC Press: Lyon, 2002; 40-43.
2. Crozat A, Aman P, Mandahl N, Ron D. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature 1993;363:640-644.
3. Knight JC, Renwick PJ, Dal Cin P, Van Den Berghe H, Fletcher CDM. Translocation t(12;16)(q13;p11) in myxoid liposarcoma and round cell liposarcoma: molecular and cytogenetic analysis. Cancer Res 1995;55:24-27.
4. Antonescu CR, Elahi A, Humphrey M, Lui MY, Healey JH, Brennan MF, et al. Specificity of TLS-CHOP rearrangement for classic myxoid/round cell liposarcoma. Absence in predominantly myxoid well-differentiated liposarcomas. J Mol Diagn 2000;2:132-138.
5. Evans H. Liposarcoma. A study of 55 cases with a reassessment of its classification. Am J Surg Pathol 1979;3:507-523.
6. Smith TA, Esley K, Goldblum JR. Myxoid/round cell liposarcoma of the extremities. A clinicopathologic study of 29 cases with particular attention to extent of round cell liposarcoma. Am J Surg Pathol 1996;20:171-180.
7. Killpartick SE, Doyon J, Choong PFM, Sim FH, Nasciment AG. The clinicopathological spectrum of myxoid and round cell liposarcoma. A study of 95 cases. Cancer 1996;77:1450-1458.
8. kip1 protein expression correlates with survival in myxoid and round-cell liposarcoma. J Clin Oncol 2000;18:2888-2893.
9. Antonescu CR, Tschernyavsky SJ, Decuseara R, Leung DH, Woodruff JM, Brennan MF, et al. Prognosis impact of p53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin Cancer Res 2001;7:3977-3987.
10. Weiss SW, Goldblum JR (eds). Enzinger and Weiss's Soft Tissue Tumors (4th edn). Mosby: St. Louis, MO, 2001; 670-687.
11. Tateishi U, Hasegawa T, Beppu Y, Kawai A, Moriyama N. Prognostic significance of grading (MIB-1 system) in patients with myxoid liposarcoma. J Clin Pathol 2003;56:579-582.
12. 1-S checkpoint in myxoid and round cell liposarcoma. Am J Pathol 1997; 151:1531-1539.
13. Nielsen GP, Burns KL, Rosenberg AE, Louis DN. CDKN2A gene deletion and loss of p16 expression occur in osteosarcoma that lack RB alterations. Am J Pathol 1998;153:159-163.
14. Tsuchiya T, Sekine K, Hinohara S, Namiki T, Nobori T, Kaneko Y. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet Cytogenet 2000;120:91-98.
15. Benassi MS, Molendini L, Gamberi G, Magagnoli G, Ragazzini P, Gobbi GA, et al. Involvement of INK4A gene products in pathogenesis and development of human osteosarcoma. Cancer 2001;15:3062-3067.
16. Birindelli S, Perrone F, Oggionni M, Lavarino C, Pasini B, Vergani B, et al. Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors. Lab Invest 2001;81:833-844.
17. Lopez-Guerrero JA, Pellin A, Noguera R, Carda C, Llombart-Bosch A. Molecular analysis of the 9p21 locus and p53 genes in Ewing family tumors. Lab Invest 2001;81:803-814.
18. Park YB, Park MJ, Kimura K, Shimizu K, Lee SH, Yokota J. Alterations in the INK4a/ARF locus and their effects on the growth of human osteosarcoma cell lines. Cancer Genet Cytogenet 2002;133:105-111.
19. INK4a gene in leiomyosarcoma of soft tissue: decreased p16 expression correlates with promoter methylation and poor prognosis. J Pathol 2003;201:487-495.
20. INK4a inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. Clin Cancer Res 2003; 9:4132-4138.
21. 1 to S-phase cell cycle checkpoint is involved in the pathogenesis of human osteosarcoma. Diagn Mol Pathol 2004;13:81-91.
22. ARF pathway in clear cell sarcoma. Cancer Sci 2004;95:651-655.
23. van Beerendonk HM, Rozeman LB, Taminiau AHM, Sciot R, Bovee JVMG, Cleton-Jansen AM, et al. Molecular analysis of the INK4A/INK4A-ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumor progression. J Pathol 2004;202:359-366.
24. Chin L, Pomerantz J, Depiho RA. The INK4a/ARF tumor suppressor: one gene - two products - two pathways. Trends Biochem Sci 1998;23:291-296.
25. ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course. Clin Cancer Res 2003;9:4884-4890.
26. ARF gene in meningiomas and its correlation to the p53 expression and mutation. Mod Pathol 2004;17:705-710.
27. Guillou L, Coindre JM, Bonichon F, Bui NB, Terrier P, Collin F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading system in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997;15:350-362.
28. Fleming ID, Cooper JS, Henson DE. Soft tissue sarcoma. In American Joint Committee on Cancer. Cancer Staging Manual (5th edn), Fleming ID, Cooper JS, Henson DE (eds). Lippincott-Raven: Philadelphia, PA, 1998; 149-156.
29. Kratzke RA, Greatens TM, Rubins JB, Maddaus MA, Niewoehner DE, Niehans GA, et al. Rb and p16INK4a expression in resected non-small cell lung tumors. Cancer Res 1996;56:3415-3420.
30. Xing EP, Nie Y, Song Y, Yang GY, Cai YC, Wang LD, et al. Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a genes in human esophageal squamous cell carcinoma. Clin Cancer Res 1999;5:2704-2713.
31. Oda Y, Sakamoto A, Saito T, Kawauchi S, Iwamoto Y, Tsuneyoshi M. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma. Mod Pathol 2000;13:994-1004.
32. Nakamura M, Sasaki T, Hashimoto H, Nakase H, Ishida E, Shimada K, et al. Frequent alterations of p14(ARF) and p16(INK4a) genes in primary central nervous system lymphomas. Cancer Res 2001;61:6335-6339.
33. ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol 2001;11:159-168.
34. Smith TA, Goldblum JR. Immunohistochemical analysis of p53 protein in myxoid/round cell liposarcomas of the extremities. Appl Immunohistochem 1996;4:228-234.
35. Pilloti S, Lavarino C, Mezzelani A, Della Torre C, Minoletti F, Sozzi G, et al. Limited role of TP53 and TP53-related genes in myxoid liposarcoma. Tumori 1998;84:571-577.
36. Antonescu CR, Leung DH, Dudas M, Ladanyi M, Brennan M, Woddruff JM, et al. Alterations of cell cycle regulators in localized synovial sarcoma. Am J Pathol 2000;156:977-983.
37. de Alava E, Antonescu CR, Panizo A, Leung D, Meyers PA, Huvos AG, et al. Prognostic impact of P53 status in Ewing's sarcoma. Cancer 2000;89:783-792.
38. Olofsson A, Willen H, Goransson M, Engstrom K, Meis-Kindblom JM, Stenman G, et al. Abnormal expression of cell cycle regulators in FUS-CHOP carrying liposarcomas. Int J Oncol 2004;25:1349-1355.
39. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 1998;95:8292-8297.
40. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998;92:725-734.